For members of the public:
Oxybutynin
Overview
The Patient Information Leaflet for products containing Oxybutynin from Teva can be downloaded below, along with other information such as Frequently Asked Questions where applicable. To contact Teva's Medical Information Service email: medinfo@tevauk.com or telephone: 0207 540 7117.
Available as
- Oral solution
- Patches
Date of preparation: April 2023
D: COB-GB-NP-00112 (V1.0) / T: COB-GB-NP-00102 (V1.0) / M: COB-GB-NP-00103 (V1.0)
Date of preparation: April 2023
D: COB-GB-00016 (V1.0) / T: COB-GB-00014 (V1.0) / M: COB-GB-00015 (V1.0)
Date of preparation: April 2023
D: COB-GB-NP-00104 (V1.0) / T: COB-GB-NP-00105 (V1.0) / M: COB-GB-NP-00106 (V1.0)